Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

160 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of cladribine on intrathecal and peripheral B and plasma cells.
Allen-Philbey K, Stephenson S, Doody G, MacDougall A, Aboulwafaali M, Ammoscato F, Andrews M, Gnanapavan S, Giovannoni G, Grigoriadou S, Hickey A, Holden DW, Lock H, Papachatzaki M, Redha I, Baker D, Tooze R, Schmierer K. Allen-Philbey K, et al. Among authors: schmierer k. Clin Exp Immunol. 2024 Dec 12:uxae116. doi: 10.1093/cei/uxae116. Online ahead of print. Clin Exp Immunol. 2024. PMID: 39663507
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty.
Arun T, Petheram K, Tallantyre E, Ford H, Chataway J, Dougall NM, Doshi A, Englezou C, Farrell R, Hughes S, McDonnell G, Murray K, Rees R, Robertson N, Schmierer K, Dobson R; Association of British Neurologists, Special interest group for MS and neuroinflammation. Arun T, et al. Among authors: schmierer k. Mult Scler Relat Disord. 2024 Dec;92:106144. doi: 10.1016/j.msard.2024.106144. Epub 2024 Nov 10. Mult Scler Relat Disord. 2024. PMID: 39579643
Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells.
Ammoscato F, Wafa M, Skonieczna J, Bestwick J, Monero R, Andrews M, De Trane S, Holden D, Adams A, Bianchi L, Turner B, Marta M, Schmierer K, Baker D, Giovannoni G, Gnanapavan S. Ammoscato F, et al. Among authors: schmierer k. Clin Immunol. 2024 Dec;269:110380. doi: 10.1016/j.clim.2024.110380. Epub 2024 Oct 18. Clin Immunol. 2024. PMID: 39428028 Free article.
MS care: integrating advanced therapies and holistic management.
Giovannoni G, Ford HL, Schmierer K, Middleton R, Stennett AM, Pomeroy I, Fisniku L, Scalfari A, Bannon C, Stross R, Hughes S, Williams A, Josephs S, Peel C, Straukiene A. Giovannoni G, et al. Among authors: schmierer k. Front Neurol. 2024 Jan 30;14:1286122. doi: 10.3389/fneur.2023.1286122. eCollection 2023. Front Neurol. 2024. PMID: 38351950 Free PMC article. Review.
Disease activity 4.5 years after starting cladribine: experience in 264 patients with multiple sclerosis.
Allen-Philbey K, De Trane S, MacDougall A, Adams A, Bianchi L, Campion T, Giovannoni G, Gnanapavan S, Holden DW, Marta M, Mathews J, Turner BP, Baker D, Schmierer K. Allen-Philbey K, et al. Among authors: schmierer k. Ther Adv Neurol Disord. 2023 Nov 10;16:17562864231200627. doi: 10.1177/17562864231200627. eCollection 2023. Ther Adv Neurol Disord. 2023. PMID: 37954917 Free PMC article.
160 results